MARKET

NKTX

NKTX

Nkarta, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

32.62
-2.05
-5.91%
Closed 16:01 07/29 EDT
OPEN
34.70
PREV CLOSE
34.67
HIGH
35.65
LOW
31.16
VOLUME
273.92K
TURNOVER
--
52 WEEK HIGH
79.16
52 WEEK LOW
22.46
MARKET CAP
959.93M
P/E (TTM)
-8.6367
1D
5D
1M
3M
1Y
5Y
Benzinga's Top Ratings Upgrades, Downgrades For July 16, 2021
 
Benzinga · 07/16 14:15
FibroGen hurt by downgrades, Danaher given Street-high target - today's analyst action
Mario13/E+ via Getty Images FibroGen courts downgrades after FDA setback for Roxadustat  FibroGen (FGEN) has lost ~35.7% in the pre-market in reaction to its failure to win the endorsement from FDA’s expert
Seekingalpha · 07/16 13:11
Oppenheimer Initiates Coverage On Nkarta with Outperform Rating, Announces Price Target of $75
Oppenheimer analyst Matthew Biegler initiates coverage on Nkarta (NASDAQ:NKTX) with a Outperform rating and announces Price Target of $75.
Benzinga · 07/16 09:05
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Benzinga · 07/15 16:45
Nkarta Unveils Plans For New San Francisco HQ, Manufacturing Site
Benzinga · 07/14 13:07
Nkarta establishes NK cell therapy manufacturing facility
Nkarta (NKTX) has signed a lease agreement for a facility to support research and development and future commercial manufacturing of the company's cell therapy pipeline.The 88K square foot facility in South San
Seekingalpha · 07/14 11:40
Nkarta 8-K Shows Co. Entered Into Triple Net Lease Between Co., HCP BTC For Lease Of Existing Office Building In San Francisco, California
On July 9, 2021, Nkarta, Inc. (the “Company”) entered into a “triple net” lease between the Company and HCP BTC, LLC (“Landlord”), pursuant to which the Company will lease an existing
Benzinga · 07/14 11:13
Nkarta Establishes New Combined NK Cell Therapy Manufacturing Facility / Company Headquarters
-- 88,000 square foot facility in South San Francisco will support scaled manufacturing of Nkarta's engineered NK cell therapy candidates, and be home to company headquarters
GlobeNewswire · 07/14 11:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NKTX. Analyze the recent business situations of Nkarta, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NKTX stock price target is 75.40 with a high estimate of 81.00 and a low estimate of 70.00.
EPS
Institutional Holdings
Institutions: 99
Institutional Holdings: 26.59M
% Owned: 90.35%
Shares Outstanding: 29.43M
TypeInstitutionsShares
Increased
38
2.10M
New
17
1.34M
Decreased
25
1.30M
Sold Out
8
1.47M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.49%
Pharmaceuticals & Medical Research
-0.31%
Key Executives
Non-Executive Chairman/Director
Ali Behbahani
President/Chief Executive Officer/Director
Paul Hastings
Chief Financial Officer
Nadir Mahmood
Senior Vice President
Ralph Brandenberger
Chief Scientific Officer
James Trager
Other
Kanya Rajangam
Secretary
Alicia Hager
Independent Director
Tiba Aynechi
Independent Director
Fouad Azzam
Independent Director
Michael Dybbs
Independent Director
Simeon George
Independent Director
Leone Patterson
Independent Director
Zachary Scheiner
Independent Director
Laura Shawver
No Data
About NKTX
Nkarta, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of allogeneic, off-the-shelf engineered natural killer (NK) and cell therapies to treat cancer. Its modular NK cell engineering platform allows it to generate new product candidates. The Company’s engineered CAR-NK cells generally consist of an NK cell engineered with a targeting receptor, OX40 costimulatory domain, CD3z signaling moiety, and mbIL-15. This platform is modular, which enables optimization of different ways to enhance the natural signaling of engineered cells, as well as the ability to attach and optimize new targeting receptors. The Company’s lead product candidates are NKX101 and NKX019. The Company’s NK cell engineering platform is designed for engineering T cells and NK cells and understanding of NK cell biology.

Webull offers kinds of Nkarta Inc stock information, including NASDAQ:NKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NKTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NKTX stock methods without spending real money on the virtual paper trading platform.